• FirefoxInstall the new Firefox »
  •  Dow Down0.23% Nasdaq Down0.27%

    Regeneron Pharmaceuticals, Inc. (REGN)

    -NasdaqGS
    448.38 Down 5.61(1.24%) 4:00PM EDT
    |After Hours : 446.60 Down 1.77 (0.40%) 7:04PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Regeneron Pharmaceuticals, Inc.
    777 Old Saw Mill River Road
    Tarrytown, NY 10591
    United States - Map
    Phone: 914-847-7000
    Website: http://www.regeneron.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:2,925

    Business Summary 

    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regeneron Pharmaceuticals, Inc.

    Corporate Governance 
    Regeneron Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Leonard S. Schleifer M.D., Ph.D., 62
    Co-Founder, Chief Exec. Officer, Pres, Exec. Director and Ex Officio Member of Technology Committee
    3.21M70.33M
    Dr. Alfred G. Gilman M.D., Ph.D., 73
    Co-Founder, Director, Chairman of Corp. Governance & Compliance Committee and Member of Technology Committee
    75.00KN/A
    Mr. Robert E. Landry Jr., 51
    Chief Financial Officer and Sr. VP of Fin.
    195.00K0.00
    Mr. George D. Yancopoulos M.D., Ph.D., 55
    Chief Scientific Officer, Pres of Regeneron Research Laboratories, Director and Member of Technology Committee
    2.92M48.86M
    Dr. Neil Stahl Ph.D., 58
    Exec. VP of R&D
    880.00K14.81M
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders